Regencell Bioscience Holdings Ltd (RGC)
6.30
+0.20
(+3.28%)
USD |
NASDAQ |
Nov 15, 16:00
6.30
0.00 (0.00%)
After-Hours: 16:55
Regencell Bioscience Holdings Enterprise Value: 71.42M for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | 71.42M |
| November 13, 2024 | 74.02M |
| November 12, 2024 | 74.41M |
| November 11, 2024 | 71.16M |
| November 08, 2024 | 82.09M |
| November 07, 2024 | 86.38M |
| November 06, 2024 | 82.22M |
| November 05, 2024 | 93.28M |
| November 04, 2024 | 97.70M |
| November 01, 2024 | 97.31M |
| October 31, 2024 | 77.92M |
| October 30, 2024 | 81.96M |
| October 29, 2024 | 86.51M |
| October 28, 2024 | 71.42M |
| October 25, 2024 | 52.55M |
| October 24, 2024 | 51.64M |
| October 23, 2024 | 54.87M |
| October 22, 2024 | 57.62M |
| October 21, 2024 | 57.10M |
| October 18, 2024 | 58.27M |
| October 17, 2024 | 55.93M |
| October 16, 2024 | 57.10M |
| October 15, 2024 | 62.57M |
| October 14, 2024 | 64.52M |
| October 11, 2024 | 73.50M |
| Date | Value |
|---|---|
| October 10, 2024 | 81.83M |
| October 09, 2024 | 60.51M |
| October 08, 2024 | 53.20M |
| October 07, 2024 | 49.30M |
| October 04, 2024 | 48.64M |
| October 03, 2024 | 55.28M |
| October 02, 2024 | 54.89M |
| October 01, 2024 | 62.18M |
| September 30, 2024 | 64.20M |
| September 27, 2024 | 64.13M |
| September 26, 2024 | 69.60M |
| September 25, 2024 | 65.11M |
| September 24, 2024 | 67.90M |
| September 23, 2024 | 67.51M |
| September 20, 2024 | 73.82M |
| September 19, 2024 | 74.41M |
| September 18, 2024 | 76.75M |
| September 17, 2024 | 81.83M |
| September 16, 2024 | 62.70M |
| September 13, 2024 | 62.31M |
| September 12, 2024 | 64.91M |
| September 11, 2024 | 71.68M |
| September 10, 2024 | 74.15M |
| September 09, 2024 | 74.41M |
| September 06, 2024 | 79.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
33.73M
Minimum
Jul 16 2024
595.80M
Maximum
Jun 15 2022
253.08M
Average
286.54M
Median
May 24 2023
Enterprise Value Benchmarks
| Sino Biopharmaceutical Ltd | 8.600B |
| HUTCHMED (China) Ltd | 2.171B |
| Pharmaron Beijing Co Ltd | -- |
| Prenetics Global Ltd | 9.425M |
| Uni-Bio Science Group Ltd | 13.51M |
Enterprise Value Related Metrics
| Earnings Yield | -5.24% |